Federal Reports

The Office of Inspector General (OIG) evaluated NASA's implementation of the recommendations made by the OIG, Government Accountability Office, and National Academy of Public Administration to improve NASA's export-control and foreign national access programs.

The objective of this audit was to determine NARA's compliance with improper payment requirements based on Office of Management and Budget Memorandum 15-02 and OMB Circular A-136.

The Utah Department of Health, Division of Medicaid and Health Financing (State agency), did not always comply with Federal Medicaid requirements for invoicing manufacturers for rebates for physician-administered drugs. The State agency did not invoice manufacturers for rebates associated with $6,188,000 ($4,387,000 Federal share) in physician-administered drugs. Of this amount, $5,189,000 ($3,679,000 Federal share) was for single-source drugs, and $999,000 ($709,000 Federal share) was for top-20 multiple-source drugs. Because the State agency's internal controls did not always ensure that it invoiced manufacturers to secure rebates, the State agency improperly claimed Federal reimbursement for these single-source drugs and top-20 multiple-source drugs.

The Connecticut Department of Social Services (State agency) did not comply with Federal waiver and State requirements for critical incidents involving developmentally disabled Medicaid beneficiaries. Specifically, the State agency did not ensure that (1) group homes reported all critical incidents to the Department of Developmental Services (DDS), (2) DDS recorded all critical incidents reported by group homes, (3) group homes always reported incidents at the correct severity level, (4) DDS collected and reviewed all data on critical incidents, and (5) DDS always reported reasonable suspicions of abuse or neglect.

The New Jersey Office of the State Comptroller, Medicaid Fraud Division, did not always suspend Medicaid payments to providers with credible allegations of fraud in accordance with the Affordable Care Act. Of the 49 providers with credible allegations of fraud that we reviewed, the Medicaid Fraud Division suspended or had good cause not to suspend Medicaid payments to 36 providers. However, it did not initiate proceedings to suspend Medicaid payments to the remaining 13 providers.